Status:
TERMINATED
COVID-19 Vaccination in Rheumatic Disease Patients
Lead Sponsor:
Mayo Clinic
Conditions:
Systemic Lupus Erythematosus
Sjogren's Syndrome
Eligibility:
All Genders
18+ years
Phase:
EARLY_PHASE1
Brief Summary
The research is being done to study the immune responses to COVID-19 vaccination in patients with rheumatic diseases.
Detailed Description
Because patients treated with immunosuppressive agents have been excluded from initial clinical trials, and most patients with rheumatic diseases are taking immunosuppressants, the immune responses to...
Eligibility Criteria
Inclusion
- Rheumatologist confirmed diagnosis of one of the following diagnoses:
- Systemic lupus erythematosus;
- Sjogren syndrome;
- Inflammatory myositis;
- Psoriatic arthritis;
- Osteoarthritis;
- Gout;
- Ankylosing spondylitis;
- IBD-related arthritis.
Exclusion
- Active infection or untreated malignancy (other than skin cancer) at enrollment.
- Pregnancy
Key Trial Info
Start Date :
February 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 9 2022
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04839315
Start Date
February 15 2021
End Date
February 9 2022
Last Update
June 3 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905